Rossari Biotech Limited has informed the Exchange regarding press release dated July 19, 2025 titled "Rossari Biotech announces Q1 FY26 results".
ROSSARI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Rossari Biotech announced its Q1 FY26 results (quarter ended June 30, 2025). On a consolidated basis, revenue from operations grew 11% YoY to Rs. 543.7 crore, while EBITDA rose 4.6% to Rs. 67.9 crore. However, PAT declined 3.7% to Rs. 33.6 crore and EBITDA margin contracted to 12.5% from 13.3%. On a standalone basis, the performance was stronger with revenue up 21.6% to Rs. 365.8 crore, EBITDA up 10.3% to Rs. 43.9 crore, and PAT up 7.8% to Rs. 26.2 crore. Management highlighted that the HPPC and AHN segments grew 16% and 12% respectively, while ongoing capacity expansion projects are progressing in phases and expected to drive growth from FY27 onwards.
Mixed quarter for shareholders — top-line growth was healthy but margin pressure and a dip in consolidated PAT may temper near-term sentiment. Standalone numbers show the underlying business is performing well, and management's commentary on capacity expansion and segment growth points to potential medium-term upside.